|
ACCESS
Atorvastatin Comparative Cholesterol Efficacy and Safety Study
 |
Author(s) |
Andrews TC, Ballantyne CM, Hsia JA, Kramer JH
|
 |
Title(s) |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins
|
|
Reference(s) |
Am J Med 2001;111:185-91 |
|
Disease |
Hypercholesterolaemia
|
|
Purpose |
To compare the efficacy and safety of five statins and their ability to reduce LDL cholesterol to the National Cholesterol Education Program (NCEP) target level
|
|
Study design |
Randomised, open, parallel-group
|
|
Follow-up |
54 weeks
|
|
Patients |
3916 patients, aged 18-80 years, with hypercholesterolaemia according to the NCEP LDL-cholesterol inclusion criteria
|
|
Treatment regimen |
Atorvastatin, 10 mg/day, or pravastatin, 10 mg/day, or simvastatin, 10 mg/day, or fluvastatin, 20 mg/day, or lovastatin, 20 mg/day. If the NCEP target was not achieved, the dose was titrated up to 40 mg/day for pravastatin and simvastatin, and to 80 mg/day for atorvastatin, fluvastatin and lovastatin
|
|
Results |
The percentage of patients who achieved their NCEP goal at week 6 (and therefore stayed on their initial dose) and continued to meet their NCEP goal at week 54 was significantly higher in the atorvastatin group (86%) than in the simvastatin group (77%; p < 0.05), the pravastatin group (69%; p < 0.05), the lovastatin group (63%; p < 0.01) and the fluvastatin group (54%; p < 0.01). No clinically significant tolerability or safety issues were observed with any of the study drugs
|
|
|
|
